Celecoxib in Treating Patients With Early-Stage Rectal Cancer
Pilot COX-2 Activity in Early Stage Rectal Cancer -Short Term Administration of Celecoxib (SPORE)
RATIONALE: Studying samples of tissue, blood, and urine from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how rectal cancer will respond to treatment with celecoxib.
PURPOSE: This clinical trial is studying how well celecoxib works in treating patients with early-stage rectal cancer.
調査の概要
状態
条件
詳細な説明
OBJECTIVES:
- Determine cyclooxygenase-2 (COX-2) over-expression in tumor specimens from patients with early-stage rectal cancer.
- Determine whether administration of a COX-2 inhibitor, celecoxib, results in changes in tumor (COX-2 overexpressing) levels of eicosanoids but not in levels in the surrounding normal tissue that is expected not to express COX-2.
- Determine whether surrogate markers of eicosanoid metabolism (i.e., serum VEGF levels, tumor prostaglandin E_2 [PGE_2], and the major urinary metabolite of PGE_2 [PGE-M]) in biological specimens from these patients correlate with changes noted in tumor tissue.
- Determine if there is a greater change in protein and gene expression from pretreatment biopsy levels in patient tumor specimens (COX-2 overexpressing) vs specimens of surrounding normal tissue (expected not to be COX-2 overexpressing).
OUTLINE: Patients receive oral celecoxib twice daily on days 1-5. Patients then undergo planned local excision or definitive radical resection on day 6.
Tumor tissue and normal tissue (at least 5 cm away from the tumor) samples are collected pretreatment. Post-treatment tissue samples are collected along with the surgery. Serum and urine samples are obtained at baseline and after administration of celecoxib. Tumor and normal tissue specimens are analyzed by assays measuring markers of cyclooxygenase-2 (COX-2) activity (i.e., COX-2 mRNA and protein, tumor prostaglandin E_2 [PGE_2], and VEGF). Tissue samples are also assessed by cDNA microarray and imaging mass spectrometry to determine overall changes in gene and protein expression from pretreatment levels. Surrogate markers of COX-2 activity in serum (i.e., VEGF) and urine (i.e., urinary metabolite of PGE_2 [PGE-M]) are also assessed and compared with changes noted in tumor tissue. COX-2 protein levels are determined by immunohistochemistry in patients with limited pretreatment tumor tissue specimens.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37232
- Vanderbilt-Ingram Cancer Center
-
Nashville、Tennessee、アメリカ、37212
- Veterans Administration
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
Clinical diagnosis of primary adenocarcinoma of the rectum (to be histologically confirmed upon study entry)
- Tumor must be at or below the peritoneal reflection
- The distal border of the tumor is within 12 cm of the anal verge on proctoscopic examination
- Clinically resectable disease
PATIENT CHARACTERISTICS:
- Karnofsky performance status 60-100%
- WBC ≥ 4,000/mm³
- Platelet count ≥ 150,000/mm³
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No other serious medical illness (other than rectal cancer) that would preclude study therapy
- No psychiatric condition that would preclude informed consent
- No history of allergy to celecoxib or any other NSAIDs, including acetylsalicylic acid (i.e., aspirin), ibuprofen, or indomethacin
- No history of allergy to sulfonamides
Exclusion criteria:
Not noted
PRIOR CONCURRENT THERAPY:
- At least 7 days since prior and no concurrent NSAIDs or other cyclooxygenase-2 inhibitors
- No concurrent warfarin, except low-dose warfarin (i.e., 1 mg/day) administered for prophylaxis
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:Therapeutic Intervention/Celecoxib
Celecoxib
|
記されていない
記されていない
Will be administered orally 400 mg po BID starting 5 days prior to planned surgical resection.
他の名前:
not noted
Not noted
At the time of preoperative evaluation by surgeon as well as one week after administration of Celecoxib.
not noted
not noted
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
---|---|
Event rate of over-expression of cyclooxygenase-2
時間枠:Pre and post 7 days administration of study drug
|
Pre and post 7 days administration of study drug
|
Percent change of eicosanoid level
時間枠:Pre and post celecoxib treatment ratio of eicosanoid production
|
Pre and post celecoxib treatment ratio of eicosanoid production
|
Percent change of VEGF and prostaglandin-M levels
時間枠:Pre and post celecoxib treatment VEGF and PGE-M levels
|
Pre and post celecoxib treatment VEGF and PGE-M levels
|
Change of gene and protein expression pattern from pre- to post-treatment levels
時間枠:Pre and post celecoxib treatment
|
Pre and post celecoxib treatment
|
協力者と研究者
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- VICC GI 0174
- VU-VICC-GI-0174
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
大腸がんの臨床試験
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); Highlight Therapeutics積極的、募集していない平滑筋肉腫 | 悪性末梢神経鞘腫瘍 | 滑膜肉腫 | 未分化多形肉腫 | 骨の未分化高悪性度多形肉腫 | 粘液線維肉腫 | II期の体幹および四肢の軟部肉腫 AJCC v8 | III期の体幹および四肢の軟部肉腫 AJCC v8 | IIIA 期の体幹および四肢の軟部肉腫 AJCC v8 | IIIB 期の体幹および四肢の軟部肉腫 AJCC v8 | 切除可能な軟部肉腫 | 多形性横紋筋肉腫 | 切除可能な脱分化型脂肪肉腫 | 切除可能な未分化多形肉腫 | 軟部組織線維肉腫 | 紡錘細胞肉腫 | ステージ I 後腹膜肉腫 AJCC (American Joint Committee on Cancer) v8 | 体幹および四肢の I 期軟部肉腫 AJCC v8 | ステージ... およびその他の条件アメリカ
質量分析の臨床試験
-
Boston University Charles River CampusSan Francisco State University完了
-
Tilburg UniversityThe Elisabeth-TweeSteden Hospital引きこもった
-
Boston UniversityNational Institute on Deafness and Other Communication Disorders (NIDCD)終了しました